Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 15/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6692157 | 0.89 | MAPK14 (0.37) | MAPK14MAPK13MEN1KMT2AHSD17B10 | |
| SCHEMBL1342077 | 0.88 | MAPK14 (0.42) | MAPK14MAPK13MEN1KMT2AHSD17B10 | |
| SCHEMBL1343261 | 0.85 | TP53 (0.44) | MEN1KMT2AHSD17B10 | |
| SCHEMBL1342446 | 0.85 | MAPK14 (0.38) | MAPK14MAPK13 | |
| SCHEMBL1343121 | 0.85 | MAPK14 (0.34) | MAPK14MAPK13MEN1KMT2AHSD17B10 | |
| SCHEMBL1340721 | 0.83 | MAPK14 (0.39) | MAPK14MAPK13 | |
| SCHEMBL2657494 | 0.82 | MAPK14 (0.38) | MAPK14MAPK13 | |
| SCHEMBL6695968 | 0.82 | MAPK14 (0.37) | MAPK14MAPK13 | |
| SCHEMBL6693599 | 0.82 | MAPK14 (0.39) | MAPK14MAPK13 | |
| SCHEMBL1342817 | 0.82 | ADRB2 (0.40) | MAPK14MAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE45670-E1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2015-09-15 | — | — | US | disclosed |
| EP-2471533-A1 | Aryl carbonyl derivatives as therapeutic agents | Novo Nordisk A/S (DK) | 2012-07-04 | — | — | EP | disclosed |
| US-20110301158-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2011-12-08 | — | — | US | disclosed |
| US-7541373-B2 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2009-06-02 | — | — | US | disclosed |
| US-7384967-B2 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-06-10 | — | — | US | disclosed |
| US-20080119454-A1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-05-22 | — | — | US | disclosed |
| US-20080119455-A1 | Aryl carbonyl derivatives as therapeutic agents | NOVO NORDISK A/S (DK) | 2008-05-22 | — | — | US | disclosed |
| US-20060183783-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2006-08-17 | — | — | US | disclosed |
| EP-1531815-A1 | GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2005-05-25 | — | — | EP | disclosed |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-06-24 | — | — | US | disclosed |
| WO-2004002481-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | NOVO NORDISK A/S (DK) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301158-A1 | ARYL CARBONYL DERIVATIVES AS THERAPEUTIC AGENTS | GCK, GCKR, PDK2 | MAPK14 1028/4885MAPK13 687/4885MEN1 4426/4885 |
| US-20080119455-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | MAPK14 1028/4885MAPK13 687/4885MEN1 4426/4885 |
| US-20060183783-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, PDK3, PDK4 | MAPK14 1220/4885MAPK13 720/4885MEN1 4547/4885 |
| US-20040122235-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | MAPK14 1028/4885MAPK13 687/4885MEN1 4426/4885 |
| US-20080119454-A1 | Aryl carbonyl derivatives as therapeutic agents | GCK, GCKR, PDK2 | MAPK14 1028/4885MAPK13 687/4885MEN1 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.